Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Irinotecan Vianex

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C! C!
C! C!

Irinotekan Testmiljö

Irinotekan

Klass : C!

Visa all info

Skriv ut

Kontakta oss

  1. Irinotecan Accord (irinotecan). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2020-04-14, cited 2020-10-15]

  2. de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S. Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. Clin Pharmacokinet. 2018;57(10):1229-1254.

  3. Santos A, Zanetta S, Cresteil T, Deroussent A, Pein F, Raymond E et al. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res. 2000;6(5):2012-20.

  4. Klein CE, Gupta E, Reid JM, Atherton PJ, Sloan JA, Pitot HC et al. Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide. Clin Pharmacol Ther. 2002;72(6):638-47.

  5. Haaz MC, Rivory LP, Riché C, Robert J. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes Differential hydrolysis for the lactone and carboxylate forms. Naunyn Schmiedebergs Arch Pharmacol. 1997;356(2):257-62.

  6. Vera Regitz-Zagrosek. Sex and Gender Differences in Pharmacology. Springer-Verlag Berlin Heidelberg; 2012.

  7. Miya T, Goya T, Fujii H, Ohtsu T, Itoh K, Igarashi T et al. Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11. Invest New Drugs. 2001;19(1):61-7.

  8. Sasaki Y, Hakusui H, Mizuno S, Morita M, Miya T, Eguchi K et al. A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Jpn J Cancer Res. 1995;86(1):101-10.

  9. Han JY, Lim HS, Park YH, Lee SY, Lee JS. Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer. 2009;63(1):115-20.

  10. Lambert A, Jarlier M, Gourgou Bourgade S, Conroy T. Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial. PLoS One. 2017;12(9):e0183288.

  11. Hohla F, Hopfinger G, Romeder F, Rinnerthaler G, Bezan A, Stättner S et al. Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review. Int J Oncol. 2014;44(1):319-26.

  12. Shiozawa T, Tadokoro J, Fujiki T, Fujino K, Kakihata K, Masatani S et al. Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey. Jpn J Clin Oncol. 2013;43(5):483-91.

  13. Díaz R, Aparicio J, Molina J, Palomar L, Giménez A, Ponce J et al. Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer: a single center experience. Med Oncol. 2006;23(3):347-57.

  14. Suzuki A, Kobayashi R, Fujii H, Iihara H, Takahashi T, Yoshida K et al. Control of Nausea and Vomiting in Patients with Colorectal Cancer Receiving Chemotherapy with Moderate Emetic Risk. Anticancer Res. 2016;36(12):6527-6533.

  15. Concise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2019-03-14.]

  1. Irinotecan Accord (irinotecan). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2020-04-14, cited 2020-10-15]
  2. de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S. Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. Clin Pharmacokinet. 2018;57(10):1229-1254.
  3. Santos A, Zanetta S, Cresteil T, Deroussent A, Pein F, Raymond E et al. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res. 2000;6(5):2012-20.
  4. Klein CE, Gupta E, Reid JM, Atherton PJ, Sloan JA, Pitot HC et al. Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide. Clin Pharmacol Ther. 2002;72(6):638-47.
  5. Haaz MC, Rivory LP, Riché C, Robert J. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes Differential hydrolysis for the lactone and carboxylate forms. Naunyn Schmiedebergs Arch Pharmacol. 1997;356(2):257-62.
  6. Vera Regitz-Zagrosek. Sex and Gender Differences in Pharmacology. Springer-Verlag Berlin Heidelberg; 2012.
  7. Miya T, Goya T, Fujii H, Ohtsu T, Itoh K, Igarashi T et al. Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11. Invest New Drugs. 2001;19(1):61-7.
  8. Sasaki Y, Hakusui H, Mizuno S, Morita M, Miya T, Eguchi K et al. A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Jpn J Cancer Res. 1995;86(1):101-10.
  9. Han JY, Lim HS, Park YH, Lee SY, Lee JS. Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer. 2009;63(1):115-20.
  10. Lambert A, Jarlier M, Gourgou Bourgade S, Conroy T. Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial. PLoS One. 2017;12(9):e0183288.
  11. Hohla F, Hopfinger G, Romeder F, Rinnerthaler G, Bezan A, Stättner S et al. Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review. Int J Oncol. 2014;44(1):319-26.
  12. Shiozawa T, Tadokoro J, Fujiki T, Fujino K, Kakihata K, Masatani S et al. Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey. Jpn J Clin Oncol. 2013;43(5):483-91.
  13. Díaz R, Aparicio J, Molina J, Palomar L, Giménez A, Ponce J et al. Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer: a single center experience. Med Oncol. 2006;23(3):347-57.
  14. Suzuki A, Kobayashi R, Fujii H, Iihara H, Takahashi T, Yoshida K et al. Control of Nausea and Vomiting in Patients with Colorectal Cancer Receiving Chemotherapy with Moderate Emetic Risk. Anticancer Res. 2016;36(12):6527-6533.
  15. Concise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2019-03-14.]